| Literature DB >> 30806162 |
Marion Gardette1,2, Simon Le Hello3,4, Patricia Mariani-Kurkdjian5, Laetitia Fabre3, François Gravey3,4, Annie Garrivier1, Estelle Loukiadis2,6, Grégory Jubelin1.
Abstract
Enterohaemorrhagic Escherichia coli (EHEC) are food-borne pathogens responsible for bloody diarrhoea and renal failure in humans. While Shiga toxin (Stx) is the cardinal virulence factor of EHEC, its production by E. coli is not sufficient to cause disease and many Shiga-toxin producing E. coli (STEC) strains have never been implicated in human infection. So far, the pathophysiology of EHEC infection is not fully understood and more knowledge is needed to characterize the "auxiliary" factors that enable a STEC strain to cause disease in humans. In this study, we applied a recombinase-based in vivo expression technology (RIVET) to the EHEC reference strain EDL933 in order to identify genes specifically induced during the infectious process, using mouse as an infection model. We identified 31 in vivo-induced (ivi) genes having functions related to metabolism, stress adaptive response and bacterial virulence or fitness. Eight of the 31 ivi genes were found to be heterogeneously distributed in EHEC strains circulating in France these last years. In addition, they are more prevalent in strains from the TOP seven priority serotypes and particularly strains carrying significant virulence determinants such as Stx2 and intimin adhesin. This work sheds further light on bacterial determinants over-expressed in vivo during infection that may contribute to the potential of STEC strains to cause disease in humans.Entities:
Keywords: EHEC; RIVET; gene prevalence; intestinal pathogen; metabolism; stress response; virulence
Mesh:
Substances:
Year: 2019 PMID: 30806162 PMCID: PMC6550539 DOI: 10.1080/21505594.2019.1582976
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882
Figure 1.Efficiency of the RIVET system in EHEC. Indicated strains carrying tnpR gene under the control of chuA promoter were grown in LB supplemented with various concentrations of 2,2ʹ-dipyridyl. After 6 h of growth, cultures were enumerated on LB plates and on LB + sucrose plates to calculate the percentage of resolved CFU. Results are presented as mean and standard deviations from at least three independent experiments. Blue and red curves represent resolution obtained from the 3 tnpR variants inserted into EDL-RES and EDL-RES1 strains, respectively.
Figure 2.Resolution of selected . EDL-RES strain carrying transcriptional fusion between indicated gene promoters and tnpR gene were either grown in vitro for 6 h in LB or were given to mice by oral gavage and feces were collected 16 h post-infection. Samples were then diluted and plated on LB plates or LB + sucrose plates to calculate the percentage of resolved CFU after in vitro growth (white bars) or following mouse challenge (black bars). Results are presented as mean and standard deviations from at least three independent experiments. Differences between in vitro and in vivo conditions were analyzed by a two-tailed unpaired t-test (*P < 0.05; **P < 0.01).
Figure 4.Impact of . Competition assays were performed by co-infecting mice with an equal mixture of EDL933 WT (SmR) and the indicated ivi gene mutant (SmR KanR). Eight days post-infection, faeces were sampled, homogenized in PBS, diluted and spotted on LB + Sm plates and LB + Sm + Kan plates to count, respectively, WT + ivi mutant and ivi mutant alone. The WT population was obtained by subtracting ivi mutant CFU from total EHEC CFU. Competitive indices (ratio WT/mutant) were calculated for each animal. Each dot represents one mouse and lines represent median values. Differences between each group and the control group agaF were analyzed by ANOVA with Fisher’s LSD test (** P < 0.01).
List of in vivo-induced genes identified in EHEC O157:H7 strain EDL933.
| Gene | ||||
|---|---|---|---|---|
| COG category | label | name | O-island | Role or putative function |
| Metabolism | ||||
| [C] | L-Ribulokinase | |||
| [C] | Large subunit of nitrite reductase | |||
| [E] | 4-Aminobutyrate aminotransferase | |||
| [E] | ||||
| [E] | α-Subunit of tryptophan synthase | |||
| [E] | Putative nitrogen-containing metabolite transporter | |||
| [E] | Member of the APC superfamily of amino acid transporters | |||
| [G] | OI#126 | Enzyme of the N-acetylgalactosamine phosphotransferase system | ||
| [H] | Cobalamin adenolsyltransferase | |||
| [H] | 4-Hydroxythreonine-4-phosphate dehydrogenase | |||
| [I] | NADH-aZoreductase | |||
| [I] | 3-Ketoacyl-CoA thiolase | |||
| [P] | Putative transporter | |||
| Information storage | ||||
| [J] | Multifunctional CCA protein | |||
| [K] | Transcriptional activator of 3-hydroxyphenylpropionic acid catabolism | |||
| [K] | Transcriptional regulator of L-arabinose transport and catabolism | |||
| [K] | Transcriptional repressor of arbutin and salicin transport | |||
| [K], [E] | Putative transcriptional regulator | |||
| [K], [T] | Transcriptional activator of nitric oxide reductase NorV | |||
| [L], [U] | - | OI#134 | Putative DNA processing protein | |
| Cellular processes and signaling | ||||
| [D] | Iron–sulphur cluster repair protein | |||
| [M] | Putative HlyD family secretion protein | |||
| [M] | Multidrug efflux system protein | |||
| [G], [E], [P], [R] | Multidrug efflux system protein | |||
| [O] | Putative collagenase | |||
| [O] | Putative glutathione | |||
| [O] | Serine endoprotease | |||
| Poorly characterized | ||||
| [R] | - | OI#111 | Uncharacterized protein | |
| [R] | Uncharacterized protein; regulated by the SOS system regulator LexA | |||
| [R] | - | OI#36 | Putative DNA packaging protein of prophage CP-933K | |
| No COG | ||||
| - | - | OI#80 | Putative adhesin/invasin | |
COG category: [C] Energy production and conversion; [D] Cell cycle control, cell division, chromosome partitioning; [E] Amino acid transport and metabolism; [G] Carbohydrate transport and metabolism; [H] Coenzyme transport and metabolism; [I] Lipid transport and metabolism; [J] Translation, ribosomal structure and biogenesis; [K] Transcription; [L] Replication, recombination and repair; [M] Cell wall/membrane/envelope biogenesis; [O] Post-translational modification, protein turnover, and chaperones; [P] Inorganic ion transport and metabolism; [R] General function prediction only; [T] Signal transduction mechanisms; [U] Intracellular trafficking, secretion, and vesicular transport.
Distribution of eight ivi genes in 51 E. coli strains grouped as commensals, InPEC or ExPEC.
| Z0964 | Z3135 | Z4070 | Z4799 | |||||
|---|---|---|---|---|---|---|---|---|
| commensal (n = 6) | 0.83 | 0.83 | 0.83 | 0.67 | 0.33 | 0 | 0.33 | 0.33 |
| InPEC (n = 31) | 0.97 | 0.97 | 0.97 | 0.74 | 0.71 | 0.52 | 0.68 | 0.35 |
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| ExPEC ( | 0.5 | 0.71 | 0.43 | 0.43 | 0.5 | 0.21 | 0.14 | 0.5 |
Values indicate the proportion of strains carrying ivi genes (columns) for each category (lines).
Distribution of the eight ivi genes in 228 EHEC strains classified by serotypes.
| Z0964 | Z3135 | Z4070 | Z4799 | |||||
|---|---|---|---|---|---|---|---|---|
| TOP 7 priority serotypes (n = 97) | 1 | 1 | 1 | 0.82 | 0.37 | 0.66 | 0.77 | 0.46 |
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| Other serotypes ( | 0.86 | 0.87 | 0.86 | 0.77 | 0.11 | 0.58 | 0.72 | 0.24 |
Values indicate the proportion of strains carrying ivi genes (columns) for each category (lines).
Figure 3.Distribution of the eight . A phylogenetic tree was constructed after a core-genome multi-alignment with all 228 STEC strains and the O157 E. coli reference genome (NC_002695). Presence of each ivi gene is indicated by different coloured forms. Phylogroups are shown by colorizing the numbering of each strain and serotypes are written. All this information is indicated at the end of each branch of the phylogenetic tree.
Co-distribution of the eight ivi genes with known virulence factors in the EHEC strain collection.
| Z0964 | Z3135 | Z4070 | Z4799 | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 1 | 0.37 | 0.71 | 0.92 | 0.67 | |
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| 0.99 | 1 | 0.99 | 0.76 | 0.23 | 0.75 | 0.75 | 0.3 | |
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| 0.73 | 0.73 | 0.73 | 0.68 | 0.1 | 0.27 | 0.56 | 0.11 | |
| | ||||||||
| | ||||||||
| 1 | 1 | 1 | 0.82 | 0.31 | 0.62 | 0.77 | 0.28 | |
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| | ||||||||
| 0.86 | 0.87 | 0.86 | 0.77 | 0.15 | 0.61 | 0.71 | 0.37 |
Values indicate the proportion of strains carrying ivi genes (columns) for each category (lines)
NB: only categories with a strain number ≥3 are shown.
Distribution of stx, eae, and the eight ivi genes in EHEC strains with regards to the symptoms they have caused in patients.
| Z0964 | Z3135 | Z4070 | Z4799 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.79 | 0.18 | 0.71 | 1 | 1 | 1 | 0.85 | 0.29 | 0.71 | 0.85 | 0.32 | |
| 0.15 | 0.55 | 0.3 | 0.49 | 0.94 | 0.94 | 0.94 | 0.82 | 0.3 | 0.61 | 0.85 | 0.42 | |
| 0.26 | 0.43 | 0.32 | 0.4 | 0.98 | 0.98 | 0.98 | 0.87 | 0.19 | 0.64 | 0.81 | 0.47 |
Values indicate the proportion of strains carrying indicated genes (columns) for each category (lines).